Skip to main content
Top
Published in: Journal of Gastroenterology 6/2017

01-06-2017 | Original Article—Liver, Pancreas, and Biliary Tract

Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study

Authors: Gyotane Umefune, Hirofumi Kogure, Tsuyoshi Hamada, Hiroyuki Isayama, Kazunaga Ishigaki, Kaoru Takagi, Dai Akiyama, Takeo Watanabe, Naminatsu Takahara, Suguru Mizuno, Saburo Matsubara, Natsuyo Yamamoto, Yousuke Nakai, Minoru Tada, Kazuhiko Koike

Published in: Journal of Gastroenterology | Issue 6/2017

Login to get access

Abstract

Background

Procalcitonin is being increasingly used to diagnose and grade acute systemic bacterial infection at an early stage of disease onset. The aim of this prospective study was to evaluate the usefulness of procalcitonin for severity grading of acute cholangitis on patient admission.

Methods

Patients with acute cholangitis were prospectively enrolled. The severity of acute cholangitis was graded on the basis of the 2013 Tokyo guidelines (Japanese Society of Hepato-Biliary-Pancreatic Surgery, 2013). We compared the ability of procalcitonin level on admission to predict moderate/severe (vs mild) or severe (vs mild/moderate) acute cholangitis with the abilities of white blood cell (WBC) count and C-reactive protein (CRP) level.

Results

Two hundred thirteen patients were analyzed, and the severity of acute cholangitis was graded as mild, moderate, and severe in 108, 76, and 29 patients respectively. Procalcitonin level, WBC count, and CRP level all increased significantly according to the severity. In the receiver operating characteristic analyses, the area under the curve for procalcitonin for severe acute cholangitis was 0.90 [95% confidence interval (CI) 0.85–0.96] and was significantly greater than that for WBC (0.62; 95% CI 0.48–0.76) and that for CRP (0.70; 95% CI 0.60–0.80). The optimal cutoff value for procalcitonin for prediction of severe acute cholangitis was 2.2 ng/mL (sensitivity 0.97; specificity 0.73; accuracy 0.77). The areas under the curve for procalcitonin, WBC, and CRP for moderate/severe acute cholangitis were not significantly different.

Conclusions

Procalcitonin predicted severe acute cholangitis better than conventional biomarkers. Severe cases for which urgent biliary drainage is indicated might be identified on admission on the basis of the cutoff values for procalcitonin suggested in this study.
Appendix
Available only for authorised users
Literature
2.
go back to reference Mosler P. Diagnosis and management of acute cholangitis. Curr Gastroenterol Rep. 2011;13(2):166–72.CrossRefPubMed Mosler P. Diagnosis and management of acute cholangitis. Curr Gastroenterol Rep. 2011;13(2):166–72.CrossRefPubMed
3.
go back to reference Tsujino T, Sugita R, Yoshida H, et al. Risk factors for acute suppurative cholangitis caused by bile duct stones. Eur J Gastroenterol Hepatol. 2007;19(7):585–8.CrossRefPubMed Tsujino T, Sugita R, Yoshida H, et al. Risk factors for acute suppurative cholangitis caused by bile duct stones. Eur J Gastroenterol Hepatol. 2007;19(7):585–8.CrossRefPubMed
4.
go back to reference Kogure H, Tsujino T, Yamamoto K, et al. Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. J Gastroenterol. 2011;46(12):1411–7.CrossRefPubMed Kogure H, Tsujino T, Yamamoto K, et al. Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. J Gastroenterol. 2011;46(12):1411–7.CrossRefPubMed
5.
go back to reference Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med. 1992;326(24):1582–6.CrossRefPubMed Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med. 1992;326(24):1582–6.CrossRefPubMed
7.
go back to reference Miura F, Takada T, Strasberg SM, et al. TG13 flowchart for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):47–54.CrossRefPubMed Miura F, Takada T, Strasberg SM, et al. TG13 flowchart for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):47–54.CrossRefPubMed
8.
go back to reference Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8.
9.
go back to reference Becker KL, Nylen ES, White JC, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512–25.CrossRefPubMed Becker KL, Nylen ES, White JC, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512–25.CrossRefPubMed
10.
go back to reference Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–52.CrossRefPubMed Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–52.CrossRefPubMed
11.
go back to reference Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34(10):2596–602.CrossRefPubMed Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34(10):2596–602.CrossRefPubMed
12.
go back to reference Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.CrossRefPubMed Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.CrossRefPubMed
13.
go back to reference Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.CrossRefPubMedPubMedCentral Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.CrossRefPubMedPubMedCentral
14.
go back to reference Liu D, Su L, Han G, et al. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0129450. Liu D, Su L, Han G, et al. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0129450.
15.
go back to reference Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012;73(3):221–7.CrossRefPubMed Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012;73(3):221–7.CrossRefPubMed
16.
go back to reference Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28(4):977–83.CrossRefPubMed Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28(4):977–83.CrossRefPubMed
17.
go back to reference Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.CrossRefPubMed Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.CrossRefPubMed
18.
go back to reference Kiriyama S, Takada T, Strasberg SM, et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013;20(1):24–34.CrossRefPubMed Kiriyama S, Takada T, Strasberg SM, et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013;20(1):24–34.CrossRefPubMed
19.
go back to reference de Wolf HK, Gunnewiek JK, Berk Y, et al. Comparison of a new procalcitonin assay from Roche with the established method on the Brahms Kryptor. Clin Chem. 2009;55(5):1043–4.CrossRefPubMed de Wolf HK, Gunnewiek JK, Berk Y, et al. Comparison of a new procalcitonin assay from Roche with the established method on the Brahms Kryptor. Clin Chem. 2009;55(5):1043–4.CrossRefPubMed
20.
go back to reference Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.PubMed Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.PubMed
21.
go back to reference Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34(6):1364–75.CrossRefPubMed Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34(6):1364–75.CrossRefPubMed
22.
go back to reference Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.CrossRefPubMed Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.CrossRefPubMed
23.
go back to reference Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.CrossRefPubMed Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.CrossRefPubMed
24.
go back to reference Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.CrossRefPubMed Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.CrossRefPubMed
25.
go back to reference Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–74. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–74.
26.
go back to reference Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.CrossRefPubMedPubMedCentral Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.CrossRefPubMedPubMedCentral
27.
go back to reference Hamano K, Noguchi O, Matsumoto Y, et al. Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. Clin Lab. 2013;59(1–2):177–83.PubMed Hamano K, Noguchi O, Matsumoto Y, et al. Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. Clin Lab. 2013;59(1–2):177–83.PubMed
28.
go back to reference Shinya S, Sasaki T, Yamashita Y, et al. Procalcitonin as a useful biomarker for determining the need to perform emergency biliary drainage in cases of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(10):777–85.CrossRefPubMed Shinya S, Sasaki T, Yamashita Y, et al. Procalcitonin as a useful biomarker for determining the need to perform emergency biliary drainage in cases of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(10):777–85.CrossRefPubMed
29.
go back to reference Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):52–8.CrossRefPubMedPubMedCentral Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):52–8.CrossRefPubMedPubMedCentral
30.
go back to reference Miura F, Takada T, Kawarada Y, et al. Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):27–34.CrossRefPubMedPubMedCentral Miura F, Takada T, Kawarada Y, et al. Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):27–34.CrossRefPubMedPubMedCentral
31.
go back to reference Sun G, Han L, Yang Y, et al. Comparison of two editions of Tokyo guidelines for the management of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(2):113–9.CrossRefPubMed Sun G, Han L, Yang Y, et al. Comparison of two editions of Tokyo guidelines for the management of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(2):113–9.CrossRefPubMed
32.
go back to reference Nishino T, Hamano T, Mitsunaga Y, et al. Clinical evaluation of the Tokyo guidelines 2013 for severity assessment of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(12):841–9.CrossRefPubMed Nishino T, Hamano T, Mitsunaga Y, et al. Clinical evaluation of the Tokyo guidelines 2013 for severity assessment of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(12):841–9.CrossRefPubMed
33.
go back to reference Muller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002;72(4):643–9.PubMed Muller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002;72(4):643–9.PubMed
34.
go back to reference Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23.CrossRefPubMed Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23.CrossRefPubMed
35.
go back to reference Kushimoto S, Gando S, Saitoh D, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care. 2013;17(6):R271. Kushimoto S, Gando S, Saitoh D, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care. 2013;17(6):R271.
37.
go back to reference Lai CC, Tan CK, Chen SY, et al. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512–5.CrossRefPubMed Lai CC, Tan CK, Chen SY, et al. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512–5.CrossRefPubMed
38.
go back to reference Smith KJ, Wateska A, Nowalk MP, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013;28(9):1157–64.CrossRefPubMedPubMedCentral Smith KJ, Wateska A, Nowalk MP, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013;28(9):1157–64.CrossRefPubMedPubMedCentral
39.
go back to reference Salek J, Livote E, Sideridis K, et al. Analysis of risk factors predictive of early mortality and urgent ERCP in acute cholangitis. J Clin Gastroenterol. 2009;43(2):171–5.CrossRefPubMed Salek J, Livote E, Sideridis K, et al. Analysis of risk factors predictive of early mortality and urgent ERCP in acute cholangitis. J Clin Gastroenterol. 2009;43(2):171–5.CrossRefPubMed
40.
go back to reference Hui CK, Lai KC, Yuen MF, et al. Acute cholangitis–predictive factors for emergency ERCP. Aliment Pharmacol Ther. 2001;15(10):1633–7.CrossRefPubMed Hui CK, Lai KC, Yuen MF, et al. Acute cholangitis–predictive factors for emergency ERCP. Aliment Pharmacol Ther. 2001;15(10):1633–7.CrossRefPubMed
Metadata
Title
Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study
Authors
Gyotane Umefune
Hirofumi Kogure
Tsuyoshi Hamada
Hiroyuki Isayama
Kazunaga Ishigaki
Kaoru Takagi
Dai Akiyama
Takeo Watanabe
Naminatsu Takahara
Suguru Mizuno
Saburo Matsubara
Natsuyo Yamamoto
Yousuke Nakai
Minoru Tada
Kazuhiko Koike
Publication date
01-06-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 6/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1278-x

Other articles of this Issue 6/2017

Journal of Gastroenterology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.